# Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer

> **NCT00365365** · PHASE2 · COMPLETED · sponsor: **Sanofi** · enrollment: 214 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Doxorubicin and cyclophosphamide (AC) + bevacizumab
- **DRUG:** Docetaxel (T) + bevacizumab
- **DRUG:** Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab
- **DRUG:** Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab
- **DRUG:** Bevacizumab and trastuzumab maintenance therapy
- **DRUG:** Bevacizumab maintenance therapy

## Key facts

- **NCT ID:** NCT00365365
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 214 (ACTUAL)
- **Last updated:** 2012-09-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00365365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00365365, "Safety & Efficacy of Three Docetaxel-Based Chemotherapy Regimens Plus Bevacizumab With or Without Trastuzumab for Adjuvant Treatment of Patients With Breast Cancer". Retrieved via AI Analytics 2026-09-03 from https://api.ai-analytics.org/clinical/NCT00365365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*